Research Antibodies

 
News Articles for Research Antibodies top ^
Vaccinated Animals Generated a Broad Spectrum of Protective Antibodies Vaccine Induces Antibodies that are at Least as Protective as Palivizumab Palivizumab Competing Antibody Response from Vaccine Protects Against Both Homologous and Heterologous Disease Strains GAITHERSBURG, Md., Oct.
Sign-up for Novavax Study Published in Vaccine: RSV F-Protein Nanoparticle Vaccine Induces Antigenic Site II Antibodies investment picks
Multiple T-cell engaging bispecific programs show potential as disease modifying treatments for acute myelogenous leukemia, B-cell lymphomas and leukemia, and multiple myeloma Xencor designates its first bispecific antibody candidate, XmAb14045 an anti-CD123xCD3, for IND-enabling studies MONROVIA, Calif.
Sign-up for Xencor Provides Data Updates on XmAb Bispecific Antibody Programs and Announces Presentations at Upcoming American Society of Hematology 2014 Annual Meeting investment picks
Abcam plc, a global leader in the manufacture and supply of innovative protein research tools and services, and Cell Marque Corporation, a provider of antibodies and reagents for diagnostic immunohistochemistry, announced today they have signed a global 10-year strategic marketing agreement for Abcam’s in vitro diagnostic (IVD) immunohistochemistry (IHC) RabMAb ® primary antibody portfolio.
Sign-up for Abcam and Cell Marque Sign Global Strategic Marketing Agreement For IVD IHC RabMAb Antibodies investment picks
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that multiple abstracts will be presented at the 56 th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in San Francisco, California, December 6-9, 2014, highlighting the following: “Antibody-drug conjugates represent an innovative and important therapeutic approach to targeting cancer.
Sign-up for Seattle Genetics to Present Clinical Data from Broad ADCETRIS® (Brentuximab Vedotin) Development Program and Novel Antibody-Drug Conjugates at ASH 2014 investment picks
Seattle Genetics, Inc. (Nasdaq: SGEN) and Genmab A/S (OMX: GEN) today announced that the companies have entered into an additional antibody-drug conjugate (ADC) collaboration.
Sign-up for Seattle Genetics and Genmab Enter Into New Antibody-Drug Conjugate Collaboration investment picks
2014/10/21
Amorfix closes private placement and receives back rights for ALS antibody therapeutic development and commercialization Canada NewsWire TORONTO , Oct.
Sign-up for Amorfix closes private placement and receives back rights for ALS antibody therapeutic development and commercialization investment picks
CAMBRIDGE, Mass., Sept.
Sign-up for Momenta Pharmaceuticals Exercises Option to Acquire Novel Antibodies From AnaptysBio investment picks
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of data from ongoing clinical trials evaluating the anti-tumor activity of pembrolizumab, the company’s investigational anti-PD-1 antibody, at the European Society of Medical Oncology (ESMO) 2014 in Madrid, Spain, September 26 – 30.
Sign-up for Merck to Present New Data in Five Tumor Types from Studies Evaluating Pembrolizumab, the Company’s Investigational Anti-PD-1 Antibody, at ESMO 2014 investment picks
REDWOOD CITY, Calif., Nov.
Sign-up for OncoMed Pharmaceuticals Granted Anti-DLL4/Anti-VEGF Bispecific Antibody Patent in the U.S. investment picks
GAITHERSBURG, Md., Sept.
Sign-up for Novavax Presents Data on RSV F Nanoparticle Vaccine Induced Monoclonal Antibody at ICAAC investment picks
SHM-XEL Platform Successfully Generates Novel Therapeutic Approach to Autoimmune Disease SAN DIEGO , Sept.
Sign-up for Momenta Pharmaceuticals Exercises Option to Acquire Novel Antibody Program from AnaptysBio investment picks
-- T-cell Killing of Human Gastric and Pancreatic Cancer Cell Lines Enhanced With Interferon-α --
Sign-up for Immunomedics Publishes Results on Immunotherapy of Solid Cancers Mediated by a Novel Bispecific Antibody investment picks
http://media.marketwire.com/attachments/201203/41309_medivation_logo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1153765&ProfileId=051205&sourceType=1 SAN FRANCISCO, CA and YAVNE, ISRAEL --
Sign-up for Medivation Inc. Licenses Clinical Stage Anti-PD-1 Immune Modulatory Monoclonal Antibody From CureTech Ltd. for Potential Applications in Oncology investment picks

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Research Antibodies
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Research Analysts  |  Next: Research Applications